GLA antibody

Catalog No. ABIN7114449

This anti-GLA antibody is a Mouse Monoclonal antibody detecting GLA in WB, IHC, ELISA and IF. Suitable for Human.

Quick Overview for GLA antibody (ABIN7114449)

Target: GLA (Galactosidase, alpha (GLA))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This GLA antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (IHC), ELISA, Immunofluorescence (IF)

Clone: 7F1

Product Details anti-GLA Antibody

Purification: Protein A+G purification

Purity: ≥95 % as determined by SDS-PAGE

Immunogen: galactosidase, alpha

Isotype: IgG2a

Application Details

Application Notes: WB: 1:500-1:2000, IHC: 1:20-1:200, IF: 1:20-1:200

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: PBS with 0.02 % sodium azide and 50 % glycerol pH 7.3,

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: -20°C for 12 months (Avoid repeated freeze / thaw cycles.)

Expiry Date: 12 months

Target Details for GLA

Target: GLA (Galactosidase, alpha (GLA))

Alternative Name: Alpha galactosidase A

Background: Synonyms:Alpha galactosidase A, galactosidase, alpha Background:GLA, also named as Melibiase, Agalsidase and Alpha-galactosidase A, belongs to the glycosyl hydrolase 27 family. It hydrolyzes terminal, non-reducing alpha-D-galactose residues in alpha-D-galactosides, including galactose oligosaccharides, galactomannans and galactolipids. Fabry disease is an X-linked lysosomal storage disorder resulting from the deficient activity of GLA. Enzyme replacement therapy(ERT) with GLA is currently the most effective therapeutic strategy for patients with Fabry disease, a lysosomal storage disease.

Molecular Weight: 49 kDa

Gene ID: 2717

UniProt: P06280

Pathways: SARS-CoV-2 Protein Interactome